[go: up one dir, main page]

PE20141032A1 - Inhibidores del virus de la hepatitis c - Google Patents

Inhibidores del virus de la hepatitis c

Info

Publication number
PE20141032A1
PE20141032A1 PE2013002447A PE2013002447A PE20141032A1 PE 20141032 A1 PE20141032 A1 PE 20141032A1 PE 2013002447 A PE2013002447 A PE 2013002447A PE 2013002447 A PE2013002447 A PE 2013002447A PE 20141032 A1 PE20141032 A1 PE 20141032A1
Authority
PE
Peru
Prior art keywords
hepatitis
compound
refers
formula
virus inhibitors
Prior art date
Application number
PE2013002447A
Other languages
English (en)
Inventor
Sheldon Hiebert
Ramkumar Rajamani
Li-Qiang Sun
Eric Mull
Eric P Gillis
Michael S Bowsher
Qian Zhao
Nicholas A Meanwell
Kishore V Renduchintala
Kandhasamy Sarkunam
Pulicharla Nagalakshmi
P V K Suresh Babu
Paul Michael Scola
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172898&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141032(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20141032A1 publication Critical patent/PE20141032A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2053—IL-8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA( I) DONDE p ES 1 - 2; m ES 0-2; n ES UN NUMERO DEL 0 AL 6; R1 ES LA FORMULA (II); X0, X1, X2 Y X3 SON CH , N, ENTRE OTROS; RA ES ALQUENILOXILO, ALCOXILO, ENTRE OTROS; RX ES METILO , ETILO; RY Y RZ SON H O HIDROXILO, ENTRE OTROS; R2 ES H, ALQUILO, HALO, ENTRE OTROS Y R3 ES H, ALCOXIALCOXICARBONILO, ALQUILCARBONILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ((2R,6S,7R,9S,13aS,14aR,16aS,Z)-14a- ((CICLOPROPILSULFONIL)CARBAMOIL)-2-((3-ISOPROPIL-4-OXO-3,4-DIHIDROFTALAZIN-1-IL)OXI)-7,9-DIMETIL-5,16-DIOXO-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-HEXADECAHIDROCICLOPROPA[e]PIRROLO[1,2-a][1,4]DIAZACICLOPENTADECIN-6-IL)CARBAMATO DE TER-BUTILO; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE POSEE UN COMPUESTO ADICIONAL COMO INTERFERON, RIBAVIRINA. DICHO COMPUESTO ES INHIBIDOR DEL VIRUS DE LA HEPATITIS C.
PE2013002447A 2011-05-05 2012-05-01 Inhibidores del virus de la hepatitis c PE20141032A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161482658P 2011-05-05 2011-05-05
US201261611171P 2012-03-15 2012-03-15
US13/459,403 US8957203B2 (en) 2011-05-05 2012-04-30 Hepatitis C virus inhibitors

Publications (1)

Publication Number Publication Date
PE20141032A1 true PE20141032A1 (es) 2014-08-27

Family

ID=46172898

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002447A PE20141032A1 (es) 2011-05-05 2012-05-01 Inhibidores del virus de la hepatitis c

Country Status (31)

Country Link
US (2) US8957203B2 (es)
EP (1) EP2705049B1 (es)
JP (1) JP6023178B2 (es)
KR (1) KR20140035383A (es)
CN (1) CN103797024B (es)
AR (1) AR086290A1 (es)
AU (1) AU2012250920B2 (es)
BR (1) BR112013028487A2 (es)
CA (1) CA2835105A1 (es)
CL (1) CL2013003171A1 (es)
CO (1) CO6821947A2 (es)
CY (1) CY1118567T1 (es)
DK (1) DK2705049T3 (es)
EA (1) EA022624B1 (es)
ES (1) ES2610967T3 (es)
HR (1) HRP20161632T1 (es)
HU (1) HUE033001T2 (es)
IL (1) IL229270B (es)
LT (1) LT2705049T (es)
MX (1) MX2013012749A (es)
PE (1) PE20141032A1 (es)
PH (1) PH12013502190A1 (es)
PL (1) PL2705049T3 (es)
PT (1) PT2705049T (es)
RS (1) RS55563B1 (es)
SG (1) SG194749A1 (es)
SI (1) SI2705049T1 (es)
SM (2) SMT201700029T1 (es)
TW (1) TWI542589B (es)
UY (1) UY34057A (es)
WO (1) WO2012151195A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
LT2882714T (lt) * 2012-08-08 2020-03-10 Merck Patent Gmbh (azo-)izochinolinono dariniai
SI2909205T1 (sl) * 2012-10-19 2017-02-28 Bristol-Myers Squibb Company 9-metil substituiran heksadekahidrociklopropa(e)pirolo(1,2-A)(1,4)diazaciklopentadecinil karbamat derivati kot nestrukturalni 3 (NS3) proteazni inhibitorji za zdravljenje hepatitis C virusnih infekcij
US9643999B2 (en) * 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914598B1 (en) * 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9409943B2 (en) * 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6342922B2 (ja) * 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
BR112015021768A2 (pt) 2013-03-15 2016-02-02 Gilead Sciences Inc inibidores do vírus da hepatite c
KR102087918B1 (ko) 2015-03-24 2020-03-12 상하이 잉리 파마슈티컬 컴퍼니 리미티드 융합 고리 유도체, 이의 제조방법, 중간체, 약물 조성물 및 응용
US11072610B2 (en) 2018-09-12 2021-07-27 Novartis Ag Antiviral pyridopyrazinedione compounds
CN118812310A (zh) * 2019-02-08 2024-10-22 大金工业株式会社 有机化合物的制造方法
CN120842223A (zh) 2019-09-26 2025-10-28 诺华股份有限公司 抗病毒吡唑并吡啶酮化合物
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
EP4361142A4 (en) 2021-06-25 2025-07-09 Hangzhou Innogate Pharma Co Ltd COMPOUND FOR USE AS A KIF18A INHIBITOR
EP4536356A1 (en) 2022-06-08 2025-04-16 Xenon Pharmaceuticals Inc. Pyridinamine derivatives and their use as potassium channel modulators

Family Cites Families (241)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0475255A3 (en) 1990-09-12 1993-04-14 F. Hoffmann-La Roche Ag Process for the preparation of optically pure (s)-alpha-((tert-butylsulfonyl)methyl)hydro cinnamic acid
DE69709671T2 (de) 1996-10-18 2002-08-22 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren von serinproteasen, insbesondere von ns3-protease des hepatitis-c-virus
JP4452401B2 (ja) 1997-08-11 2010-04-21 ベーリンガー インゲルハイム （カナダ） リミテッド Ｃ型肝炎ウイルス阻害ペプチドアナログ
EP1003775B1 (en) 1997-08-11 2005-03-16 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptides
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
ATE461207T1 (de) 2000-07-21 2010-04-15 Schering Corp Peptide als inhibitoren der ns3-serinprotease des hepatitis c virus
PE20020707A1 (es) 2000-11-20 2002-08-11 Bristol Myers Squibb Co Compuestos tripeptidicos como inhibidores de la proteasa ns3 del virus de hepatitis c
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
PL215228B1 (pl) 2002-05-20 2013-11-29 Bristol Myers Squibb Co Zwiazki tripeptydowe, ich zastosowanie i kompozycja farmaceutyczna je zawierajaca oraz jej zastosowanie
DE60334205D1 (en) 2002-05-20 2010-10-28 Bristol Myers Squibb Co Heterocyclische sulfonamid-hepatitis-c-virus-hemmer
DE60324552D1 (en) 2002-05-20 2008-12-18 Bristol Myers Squibb Co Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20060199773A1 (en) 2002-05-20 2006-09-07 Sausker Justin B Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt
US20040033959A1 (en) 2002-07-19 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical compositions for hepatitis C viral protease inhibitors
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
CN1771050A (zh) 2003-02-07 2006-05-10 益安药业 丙型肝炎丝氨酸蛋白酶的大环抑制剂
WO2004101605A1 (en) 2003-03-05 2004-11-25 Boehringer Ingelheim International Gmbh Hepatitis c inhibiting compounds
EP1599496B1 (en) 2003-03-05 2010-11-03 Boehringer Ingelheim International GmbH Hepatitis c inhibitor peptide analogs
KR20050108420A (ko) 2003-04-02 2005-11-16 베링거 인겔하임 인터내셔날 게엠베하 Ｃ형 간염 바이러스 프로테아제 억제제를 위한 약제학적조성물
ATE422895T1 (de) 2003-04-16 2009-03-15 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
EP2143727B1 (en) 2003-04-18 2015-01-21 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
EA009295B1 (ru) 2003-05-21 2007-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Соединения в качестве ингибиторов вируса гепатита с
WO2004113365A2 (en) 2003-06-05 2004-12-29 Enanta Pharmaceuticals, Inc. Hepatitis c serine protease tri-peptide inhibitors
US7125845B2 (en) 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
RS20060197A (sr) 2003-09-22 2008-09-29 Boehringer Ingelheim International Gmbh., Makrociklični peptidi koji su aktivni protiv hepatitisa c virusa
AU2004282148A1 (en) 2003-10-10 2005-04-28 Vertex Pharmaceuticals Incoporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
RS20110578A3 (en) 2003-10-14 2016-02-29 F. Hoffmann-La Roche Ltd MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
CN1902216A (zh) 2003-11-20 2007-01-24 先灵公司 丙肝病毒ns3蛋白酶的去肽化抑制剂
JP4682155B2 (ja) 2004-01-21 2011-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ウイルスに対して活性な大環状ペプチド
DE602005017582D1 (en) 2004-01-30 2009-12-24 Medivir Ab Hcv ns-3 serine protease inhibitoren
BRPI0508867A (pt) 2004-03-15 2007-09-04 Boehringer Ingelheim Int processo para a preparação de compostos macrocìclicos
BRPI0509467A (pt) 2004-03-30 2007-09-11 Intermune Inc compostos macrocìclicos como inibidores de replicação viral
WO2006016930A2 (en) 2004-05-14 2006-02-16 Intermune, Inc. Methods for treating hcv infection
EP1753775B1 (en) 2004-05-25 2012-12-26 Boehringer Ingelheim International GmbH Process for preparing acyclic hcv protease inhibitors
EP1763531A4 (en) 2004-06-28 2009-07-01 Boehringer Ingelheim Int ANALOGUE OF HEPATITIS-C INHIBITING PEPTIDES
EP1778702B1 (en) 2004-07-16 2011-07-13 Gilead Sciences, Inc. Antiviral compounds
ATE512971T1 (de) 2004-07-20 2011-07-15 Boehringer Ingelheim Int Peptidanaloga als hepatitis c-hemmer
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
CN101068828A (zh) 2004-08-27 2007-11-07 先灵公司 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的酰基磺酰胺化合物
JP2008513454A (ja) 2004-09-17 2008-05-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大環状ｈｃｖプロテアーゼインヒビターの調製方法
WO2007001406A2 (en) 2004-10-05 2007-01-04 Chiron Corporation Aryl-containing macrocyclic compounds
US20070249637A1 (en) 2004-10-21 2007-10-25 Collins Michael R Inhibitors Of Hepatitis C Virus Protease, And Compositions And Treatments Using The Same
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
DK1863833T3 (da) 2005-03-08 2013-12-02 Boehringer Ingelheim Int Fremgangsmåde til fremstilling af makrocykliske forbindelser
JP4705164B2 (ja) 2005-05-02 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｃｖｎｓ３プロテアーゼ阻害剤
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2611145A1 (en) 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation useful for treating disorders associated with hepatitis c virus
US20070021351A1 (en) 2005-06-02 2007-01-25 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
US20070004635A1 (en) 2005-06-02 2007-01-04 Schering Corporation Method of treating interferon non-responders using HCV protease inhibitor
US20060276406A1 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
AR055198A1 (es) 2005-06-02 2007-08-08 Schering Corp Formulaciones farmaceuticas y metodos de tratamiento que las utilizan
US20060276407A1 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
US20060287248A1 (en) 2005-06-02 2006-12-21 Schering Corporation Asymmetric dosing methods
US20060281689A1 (en) 2005-06-02 2006-12-14 Schering Corporation Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
WO2006130666A2 (en) 2005-06-02 2006-12-07 Schering Corporation Medicaments and methods combining a hcv protease inhibitor and an akr competitor
EP1891089B1 (en) 2005-06-02 2014-11-05 Merck Sharp & Dohme Corp. HCV protease inhibitors in combination with food
US20060276405A1 (en) 2005-06-02 2006-12-07 Schering Corporation Methods for treating hepatitis C
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI389908B (zh) 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
TW200738742A (en) 2005-07-14 2007-10-16 Gilead Sciences Inc Antiviral compounds
JP2009501732A (ja) 2005-07-20 2009-01-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎インヒビターペプチド類似体
TWI387603B (zh) 2005-07-20 2013-03-01 Merck Sharp & Dohme Ｈｃｖ ｎｓ３蛋白酶抑制劑
KR101294467B1 (ko) 2005-07-25 2013-09-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 거대고리형 억제제
US8183277B2 (en) 2005-07-29 2012-05-22 Tibotec Pharmaceuticals Ltd. Macrocylic inhibitors of hepatitis C virus
RU2441870C2 (ru) 2005-07-29 2012-02-10 Тиботек Фармасьютикалз Лтд. Макроциклические ингибиторы вируса гепатита с
JO2768B1 (en) 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus
ES2456617T3 (es) 2005-07-29 2014-04-23 Janssen R&D Ireland Inhibidores macrocíclicos del virus de la hepatitis C
RU2419619C2 (ru) 2005-07-29 2011-05-27 Медивир Аб Макроциклические ингибиторы вируса гепатита с
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
PE20070210A1 (es) 2005-07-29 2007-04-16 Tibotec Pharm Ltd Compuestos macrociclicos como inhibidores del virus de hepatitis c
ES2359939T3 (es) 2005-07-29 2011-05-30 Tibotec Pharmaceuticals Inhibidores macrocíclicos del virus de la hepatitis c.
PE20070343A1 (es) 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
PT1912997E (pt) 2005-07-29 2011-12-19 Tibotec Pharm Ltd Inibidores macrocíclicos do vírus da hepatite c
AU2006274861B2 (en) 2005-07-29 2012-11-08 Medivir Ab Macrocyclic inhibitors of hepatitis C virus
EP1915382A2 (en) 2005-08-01 2008-04-30 Phenomix Corporation Hepatitis c serine protease inhibitors and uses therefor
JP4705984B2 (ja) 2005-08-01 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｃｖｎｓ３プロテアーゼ阻害剤としての大環状ペプチド
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
PL1934243T3 (pl) 2005-09-09 2011-10-31 Boehringer Ingelheim Int Proces metatezy z zamknięciem pierścienia w zastosowaniu do wytwarzania peptydów makrocyklicznych
DE602006019323D1 (de) 2005-10-11 2011-02-10 Intermune Inc Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) * 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2007082131A1 (en) 2006-01-09 2007-07-19 Bristol-Myers Squibb Company Process for the preparation of hydroxy substituted heterocycles
JP2009528353A (ja) 2006-03-03 2009-08-06 シェーリング コーポレイション Ｈｃｖのプロテアーゼ阻害剤およびｉｒｅｓ阻害剤の医薬的組み合わせ
WO2007120595A2 (en) 2006-04-11 2007-10-25 Novartis Ag Amines for the treatment of hcv
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
US8268776B2 (en) 2006-06-06 2012-09-18 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
US20070281884A1 (en) 2006-06-06 2007-12-06 Ying Sun Macrocyclic oximyl hepatitis C protease inhibitors
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
UY30437A1 (es) 2006-06-26 2008-01-31 Enanta Pharm Inc Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
WO2008005565A2 (en) 2006-07-07 2008-01-10 Gilead Sciences, Inc. Antiviral phosphinate compounds
US7935670B2 (en) 2006-07-11 2011-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008008502A1 (en) 2006-07-13 2008-01-17 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US7635683B2 (en) 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
WO2008019303A2 (en) 2006-08-04 2008-02-14 Enanta Pharmaceuticals, Inc. Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors
CN101674844A (zh) 2006-08-04 2010-03-17 英安塔制药有限公司 四唑基大环类c型肝炎丝氨酸蛋白酶抑制剂
US20090035267A1 (en) 2007-07-31 2009-02-05 Moore Joel D Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
US20090035268A1 (en) 2007-08-01 2009-02-05 Ying Sun Tetrazolyl acyclic hepatitis c serine protease inhibitors
WO2008021960A2 (en) 2006-08-11 2008-02-21 Enanta Pharmaceuticals, Inc. Triazolyl macrocyclic hepatitis c serine protease inhibitors
US7605126B2 (en) 2006-08-11 2009-10-20 Enanta Pharmaceuticals, Inc. Acylaminoheteroaryl hepatitis C virus protease inhibitors
US7582605B2 (en) 2006-08-11 2009-09-01 Enanta Pharmaceuticals, Inc. Phosphorus-containing hepatitis C serine protease inhibitors
US20080038225A1 (en) 2006-08-11 2008-02-14 Ying Sun Triazolyl acyclic hepatitis c serine protease inhibitors
WO2008022006A2 (en) 2006-08-11 2008-02-21 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis c virus protease inhibitors
EP2079479B1 (en) 2006-10-24 2014-11-26 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
CA2667266C (en) 2006-10-24 2015-11-24 Merck & Co., Inc. Hcv ns3 protease inhibitors
EP2076278B1 (en) 2006-10-24 2015-05-06 Merck Sharp & Dohme Corp. Macrocyclic HCV NS3 protease inhibitors
KR101615500B1 (ko) 2006-10-27 2016-04-27 머크 샤프 앤드 돔 코포레이션 Ｈｃｖ ｎｓ3 프로테아제 억제제
WO2008057208A2 (en) 2006-10-27 2008-05-15 Merck & Co., Inc. Hcv ns3 protease inhibitors
US20080107625A1 (en) 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US20080107623A1 (en) 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
WO2008057995A2 (en) 2006-11-02 2008-05-15 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008070358A2 (en) 2006-11-16 2008-06-12 Phenomix Corporation N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2007321182B2 (en) 2006-11-17 2013-11-14 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis C virus
AU2008205116A1 (en) 2007-01-08 2008-07-17 Phenomix Corporation Macrocyclic hepatitis C protease inhibitors
US20080207528A1 (en) 2007-02-01 2008-08-28 Syaulan Yang Hcv protease inhibitors
EP2121674B1 (en) 2007-02-01 2010-05-12 Tibotec Pharmaceuticals Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv
SI2118098T1 (sl) 2007-02-01 2015-01-30 Janssen R&D Ireland Polimorfne oblike makrocikličnega inhibitorja HCV
DK2111396T3 (da) 2007-02-08 2013-11-04 Janssen R & D Ireland HCV-Inhiberende makrocykliske phenylcarbamater
US8937080B2 (en) 2007-02-08 2015-01-20 Medivir Ab Pyrimidine substituted macrocyclic HCV inhibitors
WO2008096002A1 (en) 2007-02-08 2008-08-14 Tibotec Pharmaceuticals Ltd. Hcv inhibiting macrocyclic phosphonates and amidophosphates
US20100087382A1 (en) 2007-02-16 2010-04-08 Boehringer Ingelheim International Gmbh Inhibitors of Hepatitis C NS3 Protease
AU2008217187A1 (en) 2007-02-20 2008-08-28 Novartis Ag Macrocyclic compounds as HCV NS3 protease inhibitors
EP2125113A2 (en) 2007-02-26 2009-12-02 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of hcv replication
CA2684086C (en) 2007-04-24 2014-05-27 F. Hoffmann-La Roche Ag Process for hcv protease inhibitor intermediate
US20080292587A1 (en) 2007-04-26 2008-11-27 Ying Sun Oximyl dipeptide hepatitis c protease inhibitors
US20080279821A1 (en) 2007-04-26 2008-11-13 Deqiang Niu Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors
US20080287449A1 (en) 2007-04-26 2008-11-20 Deqiang Niu Aza-tripeptide hepatitis c serine protease inhibitors
WO2008134395A1 (en) 2007-04-26 2008-11-06 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis c serine protease inhibitors
CL2008001274A1 (es) 2007-05-03 2008-11-03 Intermune Inc Y Array Biopharma Inc Compuestos macrolidos derivados de 5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahidrociclopropan[e]pirrolo[1,2-a][1,4]diazaciclopentadecinilo, inhibidores de la actividad de la proteasa ns3-ns4; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios y procedimiento de preparacion; y uso en el tratamiento de.....
US7932277B2 (en) 2007-05-10 2011-04-26 Intermune, Inc. Peptide inhibitors of hepatitis C virus replication
TW200918524A (en) 2007-06-29 2009-05-01 Gilead Sciences Inc Antiviral compounds
KR20100038417A (ko) 2007-06-29 2010-04-14 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
JP5465666B2 (ja) 2007-06-29 2014-04-09 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス化合物
US8927569B2 (en) 2007-07-19 2015-01-06 Merck Sharp & Dohme Corp. Macrocyclic compounds as antiviral agents
WO2009014730A1 (en) 2007-07-26 2009-01-29 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
CN104016970A (zh) 2007-10-10 2014-09-03 诺华股份有限公司 螺环吡咯烷类与其对抗hcv和hiv感染的应用
WO2009053828A2 (en) 2007-10-22 2009-04-30 Enanta Pharmaceuticals, Inc. P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors
WO2009055335A2 (en) 2007-10-25 2009-04-30 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
JP2011503201A (ja) 2007-11-14 2011-01-27 エナンタ ファーマシューティカルズ インコーポレイテッド 大環状テトラゾリルｃ型肝炎セリンプロテアーゼ阻害剤
CL2008003384A1 (es) 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
WO2009070692A1 (en) 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors
WO2009070689A1 (en) 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. Bicyclic, c5-substituted proline derivatives as inhibitors of the hepatitis c virus ns3 protease
WO2009076166A2 (en) 2007-12-05 2009-06-18 Enanta Pharmaceuticals, Inc. Oximyl hcv serine protease inhibitors
US8940688B2 (en) 2007-12-05 2015-01-27 Enanta Pharmaceuticals, Inc. Fluorinated tripeptide HCV serine protease inhibitors
MX2010006209A (es) 2007-12-05 2010-08-10 Enanta Pharm Inc Derivados de quinoxalinilo.
WO2009073713A1 (en) 2007-12-05 2009-06-11 Enanta Pharmaceuticals, Inc. Oximyl macrocyclic derivatives
WO2009073780A1 (en) 2007-12-06 2009-06-11 Enanta Pharmaceuticals, Inc. Process for making macrocyclic oximyl hepatitis c protease inhibitors
MX2010006518A (es) 2007-12-14 2010-08-10 Enanta Pharm Inc Inhibidores de serina proteasa de hepatitis c de oximil macrociclica.
US8273709B2 (en) 2007-12-14 2012-09-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic HCV serine protease inhibitors
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
EP2237666A4 (en) 2007-12-21 2012-05-16 Avila Therapeutics Inc HCV PROTEASE INHIBITORS AND USES THEREOF
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
AU2008340257B2 (en) 2007-12-21 2015-06-11 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
CA2709032C (en) 2007-12-21 2016-02-23 F. Hoffmann-La Roche Ag Process for the preparation of a macrocycle
MX2010008109A (es) 2008-01-24 2010-09-22 Enanta Pharm Inc Tripéptidos difluorizados como inhibidores de proteasa de serina de virus de hepatitis c (hcv).
WO2009094438A1 (en) 2008-01-24 2009-07-30 Enanta Pharmaceuticals, Inc. Heteroaryl-containing tripeptide hcv serine protease inhibitors
US8591878B2 (en) 2008-02-25 2013-11-26 Merck Sharp & Dohme Corp. Therapeutic compounds
WO2009117594A1 (en) 2008-03-20 2009-09-24 Enanta Pharmaceuticals, Inc. Fluorinated macrocyclic compounds as hepatitis c virus inhibitors
EP2282762A2 (en) 2008-04-15 2011-02-16 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2009134624A1 (en) 2008-04-28 2009-11-05 Merck & Co., Inc. Hcv ns3 protease inhibitors
US8211891B2 (en) 2008-04-30 2012-07-03 Enanta Pharmaceuticals, Inc. Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors
US20090285774A1 (en) 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20090285773A1 (en) 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN101580535B (zh) 2008-05-16 2012-10-03 太景生物科技股份有限公司 丙型肝炎病毒蛋白酶抑制剂
EP2300491B1 (en) 2008-05-29 2016-01-06 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
UA100436C2 (en) 2008-07-22 2012-12-25 Mepk Шарп Энд Доме Корп. Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors
EP2323981B1 (en) 2008-08-07 2014-03-12 F. Hoffmann-La Roche AG Process for the preparation of a macrocycle
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
WO2010033466A1 (en) 2008-09-16 2010-03-25 Phenomix Corporation Macrocyclic inhibitors of hepatitis c protease
WO2010031832A2 (en) 2008-09-18 2010-03-25 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
AR073603A1 (es) 2008-09-18 2010-11-17 Ortho Mcneil Janssen Pharm Combinaciones sinergicas de un inhibidor macrociclico del vhc y un nucleosido
CA2737958A1 (en) 2008-09-23 2010-04-01 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100080770A1 (en) 2008-09-29 2010-04-01 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2010059937A1 (en) 2008-11-20 2010-05-27 Achillion Pharmaceuticals, Inc. Cyclic carboxamide compounds and analogues thereof as of hepatitis c virus
US20100272674A1 (en) 2008-12-04 2010-10-28 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
MX2011006244A (es) 2008-12-10 2011-06-27 Achillion Pharmaceuticals Inc Nuevos peptidos de 4-amino-4-oxobutanoilo como inhibidores de replica viral.
AU2009324644B2 (en) 2008-12-10 2013-12-05 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2009335904A1 (en) 2008-12-19 2011-08-04 Gilead Sciences, Inc. HCV NS3 protease inhibitors
AU2009330333A1 (en) 2008-12-22 2011-07-07 Gilead Sciences, Inc. Antiviral compounds
US20100196321A1 (en) 2009-01-30 2010-08-05 Glaxosmithkline Llc Compounds
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
CA2761650C (en) 2009-05-13 2015-05-26 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis c virus inhibitors
CN101921308A (zh) 2009-06-16 2010-12-22 上海唐润医药科技有限公司 具有抗hcv活性的化合物及其用途
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
UA104195C2 (ru) 2009-07-07 2014-01-10 Берингер Ингельхайм Интернациональ Гмбх Фармацевтическая композиция ингибитора протеазы вируса гепатита c
WO2011014487A1 (en) 2009-07-30 2011-02-03 Merck Sharp & Dohme Corp. Hepatitis c virus ns3 protease inhibitors
JP5789260B2 (ja) 2009-08-27 2015-10-07 メルク・シャープ・エンド・ドーム・コーポレイション Ｃ型肝炎ウイルスのプロテアーゼ阻害薬の調製方法
NZ599133A (en) 2009-09-15 2013-10-25 Taigen Biotechnology Co Ltd Hcv protease inhibitors
RU2012117395A (ru) 2009-09-28 2013-11-10 Ф.Хоффманн-Ля Рош Лтд Новые макроциклические ингибиторы репликации вируса гепатита с
JP2013505952A (ja) 2009-09-28 2013-02-21 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新しい大環状阻害剤
US20110082182A1 (en) 2009-10-01 2011-04-07 Intermune, Inc. Therapeutic antiviral peptides
US8415374B2 (en) 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
TW201119667A (en) 2009-10-19 2011-06-16 Enanta Pharm Inc Bismacrocyclic compounds as hepatitis C virus inhibitors
WO2011063501A1 (en) 2009-11-24 2011-06-03 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
WO2011063502A1 (en) 2009-11-24 2011-06-03 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
AU2010333656B2 (en) 2009-12-18 2015-08-27 Boehringer Ingelheim International Gmbh HCV combination therapy
BR112012018897A2 (pt) 2010-01-27 2017-10-03 Ab Pharma Ltd Compostos poli-heterocíclicos altamente potentes como inibidores de hcv
WO2011150190A2 (en) 2010-05-26 2011-12-01 Anacor Pharmaceuticals, Inc. Hcv inhibitor compounds and methods of use thereof
CA2801584A1 (en) 2010-06-07 2011-12-15 Abbvie Inc. Macrocyclic hepatitis c serine protease inhibitors
US20120196794A1 (en) 2010-08-06 2012-08-02 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors
WO2012019299A1 (en) 2010-08-11 2012-02-16 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
WO2012037259A1 (en) 2010-09-15 2012-03-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
EP2618665A4 (en) 2010-09-21 2014-08-20 Merck Sharp & Dohme HCV NS3 proteinase inhibitor
NZ608720A (en) 2010-09-21 2015-03-27 Enanta Pharm Inc Macrocyclic proline derived hcv serine protease inhibitors
WO2012040242A1 (en) 2010-09-22 2012-03-29 Intermune, Inc. Substituted proline inhibitors of hepatitis c virus replication
WO2012047764A1 (en) 2010-10-04 2012-04-12 Intermune, Inc. Therapeutic antiviral peptides
US20120101032A1 (en) 2010-10-22 2012-04-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
EP2651884A2 (en) 2010-12-14 2013-10-23 Merck Sharp & Dohme Corp. Process and intermediates for preparing macrolactams
CN103380132B (zh) 2010-12-30 2016-08-31 益安药业 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2650223T3 (es) 2011-05-27 2018-01-17 Bristol-Myers Squibb Company Tripéptidos que incorporan deuterio como inhibidores del virus de la hepatitis C
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9238604B2 (en) 2011-08-19 2016-01-19 Merck Sharp & Dohme Corp. Process and intermediates for preparing macrolactams
US9328138B2 (en) 2011-11-15 2016-05-03 Msd Italia S.R.L. HCV NS3 protease inhibitors
WO2013106689A1 (en) 2012-01-12 2013-07-18 Ref Pharma, Llc. Hcv ns3 protease inhibitors
CN102617705B (zh) 2012-02-16 2014-12-31 上海纬诺医药科技有限公司 抑制丙肝病毒复制的大环类化合物

Also Published As

Publication number Publication date
PT2705049T (pt) 2017-01-23
SMT201700029T1 (it) 2017-03-08
US8957203B2 (en) 2015-02-17
SMT201700029B (it) 2017-03-08
IL229270A0 (en) 2014-01-30
SG194749A1 (en) 2013-12-30
PH12013502190A1 (en) 2021-08-09
LT2705049T (lt) 2017-01-10
MX2013012749A (es) 2013-11-20
SI2705049T1 (sl) 2017-02-28
CL2013003171A1 (es) 2014-04-11
PL2705049T3 (pl) 2017-05-31
CO6821947A2 (es) 2013-12-31
EA201391637A1 (ru) 2014-03-31
US20150125422A1 (en) 2015-05-07
KR20140035383A (ko) 2014-03-21
TWI542589B (zh) 2016-07-21
RS55563B1 (sr) 2017-05-31
AR086290A1 (es) 2013-12-04
EA022624B1 (ru) 2016-02-29
WO2012151195A1 (en) 2012-11-08
CN103797024B (zh) 2016-06-01
IL229270B (en) 2018-04-30
UY34057A (es) 2012-11-30
HRP20161632T1 (hr) 2017-01-13
AU2012250920A1 (en) 2014-01-09
ES2610967T3 (es) 2017-05-04
JP2014518858A (ja) 2014-08-07
BR112013028487A2 (pt) 2016-09-06
JP6023178B2 (ja) 2016-11-09
US9527885B2 (en) 2016-12-27
AU2012250920B2 (en) 2016-11-03
EP2705049B1 (en) 2016-10-19
NZ618594A (en) 2015-02-27
CY1118567T1 (el) 2017-07-12
EP2705049A1 (en) 2014-03-12
HUE033001T2 (en) 2017-11-28
TW201307351A (zh) 2013-02-16
CA2835105A1 (en) 2012-11-08
CN103797024A (zh) 2014-05-14
US20130115190A1 (en) 2013-05-09
DK2705049T3 (en) 2017-02-06

Similar Documents

Publication Publication Date Title
PE20141032A1 (es) Inhibidores del virus de la hepatitis c
ZA202207262B (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
DOP2019000218A (es) Inhibidores de las proteasas de serina del vhc derivados de prolinas macrocíclicas
MX362060B (es) Compuestos antivirales inhibidores del virus de hepatitis c (vhc) ns5b.
UY30392A1 (es) Compuestos de oximilo macrociclico inhibidores de proteasa de hepatitis c
ECSP12011684A (es) Inhibidores de los virus flaviviridae.
UY30437A1 (es) Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
AR084393A1 (es) Metodos para tratar el virus de la hepatitis c, composicion, uso, combinacion, kit y uno o mas compuestos anti vhc
UA112140C2 (uk) Нуклеозидні похідіні (варіанти), фармацевтична композиція на їх основі, спосіб лікування вірусної інфекції та застосування сполуки для виробництва лікарського засобу
PE20140522A1 (es) Derivados de nucleosidos 2'- sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
MA37712A2 (fr) Inhibiteurs macrocycliques de virus flaviviridae
ECSP077648A (es) Tetrazolilos macrociclicos como inhibidores de serina proteasa de hepatitis c
EA201390822A1 (ru) Макроциклические ингибиторы вирусов flaviviridae
UY30127A1 (es) Derivados de acidos antranilicos fenoxi y feniltio, composiciones farmaceuticas que los contienen y su uso.
CL2012001230A1 (es) Compuestos derivados de biciclos, inhibidores de la proteina ns5a; composicion farmaceutica que los comprende; uso en el tratamiento de la hepatitis c.
GEP20247600B (en) B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
ECSP12012104A (es) Inhibidores de virus flaviviridae
BR112013003101A2 (pt) inibidores do vírus da hepatite c
AR073701A1 (es) Derivados de indol y de indolicina, metodos para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades neurodegenerativas.
CO6551708A2 (es) Procedimiento para la preparaci´n de {4.6- diamino-2-[1-(2- fluorobencil)-1h- pirazolo[3.4-b] piridin -3-il-]pirimidin -5-il} metilcarbamato de metilo y su purificación para su uso como principio famacéutico
EA201201031A1 (ru) Ингибиторы вируса гепатита с
EA201290575A1 (ru) Ингибиторы вирусов flaviviridae
AR087182A1 (es) DERIVADOS DE INDOL SUSTITUIDOS COMO MODULADORES DE g SECRETASA
ECSP077649A (es) Piridazinonilos macrociclicos como inhibidores de serina proteasa de hepatitis c
MX373713B (es) Compuestos pirazolopirimidina.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed